5.3. Timing of Analyses On 12 December 2017, Aduro decided to cease development activities of CRS -207 and close out ongoing studies. As of 19 January 2018 every subject had completed their end of treatment visit except for 3 subjects who will have the option to continue study - drug treatment based on agreement between the Investigator and patient. All data through 19 January 2018 will be cleaned and soft -locked for CSR synopsis reporting. Additional data collection will be ongoing for these 3 subjects through to the date of database soft -lock. Additional data following database lock will be captured in an amendment to the final CSR synopsis once the 3 subjects have completed their end of study follow -up. This ASAP details the analysis plans for the CSR synopsis . 5.4. Subject Disposition Subject disposition will be presented by overall and cohort (Cohort 1 and Cohort 2). The number of subjects in Safety A nalysis set; number who completed Treatment Course 1; number who received MV ; number who discontinued Course 1 and the Treatment Period; and reasons for Course 1 and Treatment Period discontinuation will be summarized using frequency count s and percent ages . Time on study (first dose to EOS visit) and duration on treatment will be summarized. 5.5. Demographic and Baseline Characteristics Subject demographic and baseline characteristics will be summarized by cohort and overall based on the Safety Analysis set . Age, sex, ethnicity, race, and baseline weight, height , body mass index (BMI), and body surface area (BSA) will be summarized using descriptive statistics . Summaries will be produced for the FAS. The following formulas will be used for derivation and/or data conversion: Height (in cm) = height (in inches) * 2.54 Weight (in kg) = weight (in lbs) * 0.4536 BMI (kg/m2) = weight(kg)/[height(m)2] Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 17 of 24 04MAY2018 BSA(m2) = √[(height(cm)*weight(kg))/3600] Disease characteristics at baseline will be summarized. Time from diagnosis of primary tumor will be summarized using descriptive statistics methods. Time from the date of diagnosis of primary tumor to consent date (inclusive) will be displayed in months Primary site of cancer, histology, TNM classification at diagnosis and study entry, stage at diagnosis and study entry, extent of disease, baseline tumor measurements (sum of longest diameter in target lesions per RECIST 1.1, total tumor thickness measurements, and total sum of assessments per modified RECIST for MPM), number and percentage of subjects with prior radiation and prior surgery, screening PFTs, and baseline ECOG will be summarized. Additional diagnosis data will be listed.